Abstract
The treatment of chronic pain with new therapies that lack the side effects of existing analgesics is one of medicine's great unmet needs. Toward this goal, antagonists of the transient receptor potential vanilloid-1 (TRPV1) channel have shown some promise. However, the development of these compounds has been hindered by an unpleasant on-target hyperthermic side effect. With compelling evidence, the accompanying critical review by Romanovsky et al. (p. 228) regarding TRPV1 takes a position on the sites of action of TRPV1 agonists and antagonists on the thermoregulatory system that controls this side effect. From this comes insight on potential ways to overcome the unwanted hyperthermic action of TRPV1 antagonists.
- TRPV1, transient receptor potential vanilloid-1
- POA, preoptic area
- AM404, N-(4-hydroxyphenyl)-arachidonylamide
- AMG0347, (2E)-N-(7-hydroxy-5,6,7,8-tetrahydro-1-naphthalenyl)-3-(2-(1-piperidinyl)-6-(trifluoromethyl)-3-pyridinyl)-2-propenamide
- AMG 517, N-(4-((6-(4-(trifluoromethyl)phenyl)-4-pyrimidinyl)oxy)-1,3-benzothiazol-2-yl)-acetamide
- AMG8562, (2E)-N-((2R)-2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(1-piperidinyl)-4-(trifluoromethyl)phenyl)-2-propenamide
- AMG7905, N-(6-(2-((cyclohexylmethyl)amino)-4-(trifluoromethyl)phenyl)-4-pyrimidinyl)-1,3-benzothiazol-6-amine
- © 2009 by The American Society for Pharmacology and Experimental Therapeutics
PharmRev articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement